JP2023540464A5 - - Google Patents
Info
- Publication number
- JP2023540464A5 JP2023540464A5 JP2023512663A JP2023512663A JP2023540464A5 JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5 JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010706505.5A CN113952473A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| CN202010706658.XA CN113952474A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| PCT/IB2021/000498 WO2022018516A1 (en) | 2020-07-21 | 2021-07-20 | Composition and method for treating eye diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023540464A JP2023540464A (ja) | 2023-09-25 |
| JPWO2022018516A5 JPWO2022018516A5 (https=) | 2024-07-26 |
| JP2023540464A5 true JP2023540464A5 (https=) | 2024-07-26 |
| JP7842082B2 JP7842082B2 (ja) | 2026-04-07 |
Family
ID=79728536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512663A Active JP7842082B2 (ja) | 2020-07-21 | 2021-07-20 | 眼疾患を処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295243A1 (https=) |
| EP (1) | EP4185333A4 (https=) |
| JP (1) | JP7842082B2 (https=) |
| CN (1) | CN116323949A (https=) |
| AU (1) | AU2021313839A1 (https=) |
| CA (1) | CA3186830A1 (https=) |
| WO (1) | WO2022018516A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2025506383A (ja) * | 2022-02-02 | 2025-03-11 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
| JP2026509829A (ja) * | 2023-03-10 | 2026-03-25 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 昆虫細胞における組換えアデノ随伴ウイルス（ｒＡＡＶ）産生 |
| AU2024315262A1 (en) * | 2023-08-03 | 2026-02-26 | Arcum Vision Inc. | Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004037611B4 (de) * | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
| WO2006015789A2 (de) * | 2004-08-03 | 2006-02-16 | Geneart Ag | Verfahren zur modulation der genexpression durch änderung des cpg gehalts |
| CN105026433B (zh) * | 2014-01-24 | 2018-10-19 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| CA2977355A1 (en) * | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| DK3471780T3 (da) * | 2016-06-16 | 2020-11-23 | Adverum Biotechnologies Inc | Behandling af amd med aav2-variant med aflibercept |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| DK3717636T5 (da) * | 2017-11-27 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese |
| MX2020006435A (es) * | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| CA3094465A1 (en) * | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| WO2020102645A1 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus for treating pompe disease |
| FI4027983T3 (fi) * | 2019-09-11 | 2026-02-03 | Adverum Biotechnologies Inc | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla |
| MX2023004377A (es) * | 2020-10-16 | 2023-06-28 | Gyroscope Therapeutics Ltd | Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad. |
| CA3210368A1 (en) * | 2021-04-09 | 2022-10-13 | Shengjiang Liu | Compositions and methods for ocular transgene expression |
| KR20240004316A (ko) * | 2021-04-27 | 2024-01-11 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | 혈관신생과 관련된 안구 질환의 치료를 위한 조성물 및 방법 |
| MX2023014041A (es) * | 2021-05-28 | 2023-12-15 | Shanghai Regenelead Therapies Co Ltd | Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion. |
-
2021
- 2021-07-20 JP JP2023512663A patent/JP7842082B2/ja active Active
- 2021-07-20 AU AU2021313839A patent/AU2021313839A1/en active Pending
- 2021-07-20 WO PCT/IB2021/000498 patent/WO2022018516A1/en not_active Ceased
- 2021-07-20 CA CA3186830A patent/CA3186830A1/en active Pending
- 2021-07-20 CN CN202180064547.6A patent/CN116323949A/zh active Pending
- 2021-07-20 EP EP21845723.2A patent/EP4185333A4/en active Pending
-
2023
- 2023-01-20 US US18/157,599 patent/US20230295243A1/en active Pending